Amedeo Smart

Free Medical Literature Service


 

Amedeo

Alzheimer's Disease

  Free Subscription

Articles published in
Nat Med
    August 2022
  1. MILA-ALOMA M, Ashton NJ, Shekari M, Salvado G, et al
    Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease.
    Nat Med. 2022 Aug 11. pii: 10.1038/s41591-022-01925.
    >> Share

    July 2022
  2. SCHINDLER SE, Karikari TK
    Comorbidities confound Alzheimer's blood tests.
    Nat Med. 2022 Jul 4. pii: 10.1038/s41591-022-01875.
    >> Share

  3. MIELKE MM, Dage JL, Frank RD, Algeciras-Schimnich A, et al
    Performance of plasma phosphorylated tau 181 and 217 in the community.
    Nat Med. 2022;28:1398-1405.
    >> Share

    February 2022
  4. O'LEARY K
    Mapping the mediators of Alzheimer's disease.
    Nat Med. 2022 Feb 28. pii: 10.1038/d41591-022-00037.
    >> Share

    September 2021
  5. PASCOAL TA, Benedet AL, Ashton NJ, Kang MS, et al
    Microglial activation and tau propagate jointly across Braak stages.
    Nat Med. 2021;27:1592-1599.
    >> Share

  6. PERLMUTTER JS
    Aducanumab: look before leaping.
    Nat Med. 2021;27:1499.
    >> Share

  7. CUMMINGS J
    Why aducanumab is important.
    Nat Med. 2021;27:1498.
    >> Share

    August 2021
  8. JABBARI E, Duff KE
    Tau-targeting antibody therapies: too late, wrong epitope or wrong target?
    Nat Med. 2021;27:1341-1342.
    >> Share

    July 2021
  9. RABINOVICI GD
    Dominantly inherited Alzheimer's disease: a compass for drug development.
    Nat Med. 2021 Jul 5. pii: 10.1038/s41591-021-01434.
    >> Share

    June 2021
  10. SALLOWAY S, Farlow M, McDade E, Clifford DB, et al
    A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Nat Med. 2021 Jun 21. pii: 10.1038/s41591-021-01369.
    >> Share

  11. HANSSON O
    Biomarkers for neurodegenerative diseases.
    Nat Med. 2021;27:954-963.
    >> Share

    May 2021
  12. PALMQVIST S, Tideman P, Cullen N, Zetterberg H, et al
    Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
    Nat Med. 2021 May 24. pii: 10.1038/s41591-021-01348.
    >> Share

    April 2021
  13. VOGEL JW, Young AL, Oxtoby NP, Smith R, et al
    Four distinct trajectories of tau deposition identified in Alzheimer's disease.
    Nat Med. 2021 Apr 29. pii: 10.1038/s41591-021-01309.
    >> Share

    January 2021
  14. DUJARDIN S, Commins C, Lathuiliere A, Beerepoot P, et al
    Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.
    Nat Med. 2021 Jan 29. pii: 10.1038/s41591-021-01251.
    >> Share

    November 2020
  15. ARNOLD C
    Post-hoc analysis could give new life to the Alzheimer's drug aducanumab.
    Nat Med. 2020 Nov 2. pii: 10.1038/d41591-020-00031.
    >> Share

    June 2020
  16. DUJARDIN S, Commins C, Lathuiliere A, Beerepoot P, et al
    Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.
    Nat Med. 2020 Jun 22. pii: 10.1038/s41591-020-0938.
    >> Share

    May 2020
  17. ZHOU Y, Song WM, Andhey PS, Swain A, et al
    Author Correction: Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.
    Nat Med. 2020 May 14. pii: 10.1038/s41591-020-0922.
    >> Share

    April 2020
  18. JOHNSON ECB, Dammer EB, Duong DM, Ping L, et al
    Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation.
    Nat Med. 2020 Apr 13. pii: 10.1038/s41591-020-0815.
    >> Share

    March 2020
  19. BATEMAN RJ, Barthelemy NR, Horie K
    Another step forward in blood-based diagnostics for Alzheimer's disease.
    Nat Med. 2020 Mar 4. pii: 10.1038/s41591-020-0797.
    >> Share

  20. THIJSSEN EH, La Joie R, Wolf A, Strom A, et al
    Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.
    Nat Med. 2020 Mar 2. pii: 10.1038/s41591-020-0762.
    >> Share

  21. JANELIDZE S, Mattsson N, Palmqvist S, Smith R, et al
    Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.
    Nat Med. 2020 Mar 2. pii: 10.1038/s41591-020-0755.
    >> Share

  22. BARTHELEMY NR, Li Y, Joseph-Mathurin N, Gordon BA, et al
    A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease.
    Nat Med. 2020;26:398-407.
    >> Share

    January 2020
  23. ZHOU Y, Song WM, Andhey PS, Swain A, et al
    Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.
    Nat Med. 2020;26:131-142.
    >> Share

    November 2019
  24. ARBOLEDA-VELASQUEZ JF, Lopera F, O'Hare M, Delgado-Tirado S, et al
    Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report.
    Nat Med. 2019 Nov 4. pii: 10.1038/s41591-019-0611.
    >> Share

  25. ZALOCUSKY KA, Nelson MR, Huang Y
    An Alzheimer's-disease-protective APOE mutation.
    Nat Med. 2019 Nov 4. pii: 10.1038/s41591-019-0634.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016